000143228 001__ 143228
000143228 005__ 20240229112545.0
000143228 0247_ $$2doi$$a10.1093/ajcn/nqy223
000143228 0247_ $$2pmid$$apmid:30668630
000143228 0247_ $$2ISSN$$a0002-9165
000143228 0247_ $$2ISSN$$a0095-9871
000143228 0247_ $$2ISSN$$a1938-3207
000143228 0247_ $$2ISSN$$a1938-3215
000143228 0247_ $$2altmetric$$aaltmetric:54227658
000143228 037__ $$aDKFZ-2019-00827
000143228 041__ $$aeng
000143228 082__ $$a570
000143228 1001_ $$0P:(DE-HGF)0$$aJung, Audrey Y$$b0$$eFirst author
000143228 245__ $$aAntioxidant supplementation and breast cancer prognosis in postmenopausal women undergoing chemotherapy and radiation therapy.
000143228 260__ $$aOxford$$bOxford University Press$$c2019
000143228 3367_ $$2DRIVER$$aarticle
000143228 3367_ $$2DataCite$$aOutput Types/Journal article
000143228 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1554212834_30312
000143228 3367_ $$2BibTeX$$aARTICLE
000143228 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143228 3367_ $$00$$2EndNote$$aJournal Article
000143228 520__ $$aThere is a paucity of information on the prevalence of dietary supplement use in breast cancer survivors. Only a few studies have examined the impact of dietary supplements, particularly antioxidants, on breast cancer prognosis and the results are inconclusive.We examined pre- and postdiagnosis use of supplements in postmenopausal breast cancer survivors in Germany and investigated associations between postdiagnosis use of antioxidants and other supplements, and prognosis (total and breast cancer mortality, and recurrence-free survival) both overall and in women who received chemotherapy and radiation therapy.Data from 2223 postmenopausal women diagnosed with nonmetastatic breast cancer from the population-based Mamma Carcinoma Risk Factor Investigation (MARIE) study were used. Women were interviewed at recruitment in 2002-2005 and again in 2009 and followed-up until 30 June 2015. Multivariate Cox regression analysis was used to estimate HRs and corresponding 95% CIs.Pre- and postdiagnosis supplement use was reported by 36% and 45% of the women, respectively. There were 240 deaths (134 from breast cancer) and 200 breast cancer recurrences after a median follow-up time of 6.0 y after the 2009 re-interview. After adjusting for relevant confounders, concurrent antioxidant use with chemotherapy or radiation therapy among 1940 women was associated with increased risk of total mortality (HR: 1.64; 95% CI: 1.01, 2.66) and worsened recurrence-free survival (HR: 1.84; 95% CI: 1.26, 2.68). Overall postdiagnosis supplement use was not associated with breast cancer prognosis.Antioxidant use during chemotherapy or radiation therapy was associated with worsened breast cancer prognosis in postmenopausal women. There was no overall association between postdiagnosis supplement use and breast cancer prognosis. Results from our study align with the current recommendation to possibly avoid the use of antioxidants during chemotherapy or radiation therapy.
000143228 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143228 588__ $$aDataset connected to CrossRef, PubMed,
000143228 7001_ $$0P:(DE-HGF)0$$aCai, Xinting$$b1
000143228 7001_ $$aThoene, Kathrin$$b2
000143228 7001_ $$aObi, Nadia$$b3
000143228 7001_ $$0P:(DE-He78)e16e2a17f7dd2e7f7e917c0382f19b2d$$aJaskulski, Stefanie$$b4$$udkfz
000143228 7001_ $$0P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aBehrens, Sabine$$b5$$udkfz
000143228 7001_ $$aFlesch-Janys, Dieter$$b6
000143228 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b7$$eLast author$$udkfz
000143228 773__ $$0PERI:(DE-600)1496439-9$$a10.1093/ajcn/nqy223$$gVol. 109, no. 1, p. 69 - 78$$n1$$p69 - 78$$tThe American journal of clinical nutrition$$v109$$x1938-3207$$y2019
000143228 909CO $$ooai:inrepo02.dkfz.de:143228$$pVDB
000143228 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143228 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143228 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e16e2a17f7dd2e7f7e917c0382f19b2d$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143228 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000143228 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000143228 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143228 9141_ $$y2019
000143228 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J CLIN NUTR : 2017
000143228 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143228 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143228 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143228 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143228 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143228 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143228 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143228 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143228 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143228 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143228 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143228 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bAM J CLIN NUTR : 2017
000143228 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000143228 980__ $$ajournal
000143228 980__ $$aVDB
000143228 980__ $$aI:(DE-He78)C020-20160331
000143228 980__ $$aUNRESTRICTED